{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T15:20:49Z","timestamp":1750605649801},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,13]]},"DOI":"10.7759\/cureus.43426","type":"journal-article","created":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T16:54:00Z","timestamp":1691945640000},"source":"Crossref","is-referenced-by-count":5,"title":["Low-Dose Naltrexone Use in Postural Orthostatic Tachycardia Syndrome: A Case Series"],"prefix":"10.7759","author":[{"given":"Samantha J","family":"Stallkamp Tidd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Cantrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brady D","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2021.102828","article-title":"Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1","volume":"235","author":"Vernino S","year":"2021","unstructured":"Vernino S, Bourne KM, Stiles LE, et al.. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. Auton Neurosci. 2021, 235:10.1016\/j.autneu.2021.102828","journal-title":"Auton Neurosci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13245","article-title":"Postural orthostatic tachycardia syndrome is associated with significant employment and economic loss","volume":"290","author":"Bourne KM","year":"2021","unstructured":"Bourne KM, Chew DS, Stiles LE, et al.. Postural orthostatic tachycardia syndrome is associated with significant employment and economic loss. J Intern Med. 2021, 290:203-12. 10.1111\/joim.13245","journal-title":"J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2020.06.013","article-title":"Functional capacity and quality of life in the postural tachycardia syndrome: a retrospective cross-sectional study","volume":"56","author":"Hutt E","year":"2020","unstructured":"Hutt E, Vajapey R, Van Iterson EH, Jaeger F, Cho L, Ahmed HM, Mayuga KA. Functional capacity and quality of life in the postural tachycardia syndrome: a retrospective cross-sectional study. Ann Med Surg (Lond). 2020, 56:72-6. 10.1016\/j.amsu.2020.06.013","journal-title":"Ann Med Surg (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2018.02.005","article-title":"Postural tachycardia syndrome - diagnosis, physiology, and prognosis","volume":"215","author":"Arnold AC","year":"2018","unstructured":"Arnold AC, Ng J, Raj SR. Postural tachycardia syndrome - diagnosis, physiology, and prognosis. Auton Neurosci. 2018, 215:3-11. 10.1016\/j.autneu.2018.02.005","journal-title":"Auton Neurosci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-021-00798-2","article-title":"Long-COVID postural tachycardia syndrome: an American Autonomic Society statement","volume":"31","author":"Raj SR","year":"2021","unstructured":"Raj SR, Arnold AC, Barboi A, et al.. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. Clin Auton Res. 2021, 31:365-8. 10.1007\/s10286-021-00798-2","journal-title":"Clin Auton Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.01.025","article-title":"Efficacy of therapies for postural tachycardia syndrome: a systematic review and meta-analysis","volume":"93","author":"Wells R","year":"2018","unstructured":"Wells R, Elliott AD, Mahajan R, Page A, Iodice V, Sanders P, Lau DH. Efficacy of therapies for postural tachycardia syndrome: a systematic review and meta-analysis. Mayo Clin Proc. 2018, 93:1043-53. 10.1016\/j.mayocp.2018.01.025","journal-title":"Mayo Clin Proc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2021.102836","article-title":"Postural orthostatic tachycardia syndrome (POTS): priorities for POTS care and research from a 2019 National Institutes of Health Expert Consensus Meeting - Part 2","volume":"235","author":"Raj SR","year":"2021","unstructured":"Raj SR, Bourne KM, Stiles LE, et al.. Postural orthostatic tachycardia syndrome (POTS): priorities for POTS care and research from a 2019 National Institutes of Health Expert Consensus Meeting - Part 2. Auton Neurosci. 2021, 235:10.1016\/j.autneu.2021.102836","journal-title":"Auton Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2086","article-title":"The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders","volume":"38","author":"Patten DK","year":"2018","unstructured":"Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. Pharmacotherapy. 2018, 38:382-9. 10.1002\/phar.2086","journal-title":"Pharmacotherapy"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnad074","article-title":"Low dose naltrexone's utility for non-cancer centralized pain conditions - a scoping review","author":"Rupp A","year":"2023","unstructured":"Rupp A, Young E, Chadwick AL. Low dose naltrexone's utility for non-cancer centralized pain conditions - a scoping review. Pain Med. 2023, 10.1093\/pm\/pnad074","journal-title":"Pain Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4110","article-title":"A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study","volume":"26","author":"Raknes G","year":"2017","unstructured":"Raknes G, Sm\u00e5brekke L. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study. Pharmacoepidemiol Drug Saf. 2017, 26:136-42. 10.1002\/pds.4110","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-221405","article-title":"Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment","volume":"2018","author":"Weinstock LB","year":"2018","unstructured":"Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018, 2018:10.1136\/bcr-2017-221405","journal-title":"BMJ Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100485","article-title":"Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study","volume":"24","author":"O'Kelly B","year":"2022","unstructured":"O'Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health. 2022, 24:10.1016\/j.bbih.2022.100485","journal-title":"Brain Behav Immun Health"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-008-9402-x","article-title":"Cognitive interviewing in the evaluation of fatigue items: results from the patient-reported outcomes measurement information system (PROMIS)","volume":"17","author":"Christodoulou C","year":"2008","unstructured":"Christodoulou C, Junghaenel DU, DeWalt DA, Rothrock N, Stone AA. Cognitive interviewing in the evaluation of fatigue items: results from the patient-reported outcomes measurement information system (PROMIS). Qual Life Res. 2008, 17:1239-46. 10.1007\/s11136-008-9402-x","journal-title":"Qual Life Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-021-02812-6","article-title":"Cross-specialty PROMIS-global health differential item functioning","volume":"30","author":"Gregory JJ","year":"2021","unstructured":"Gregory JJ, Werth PM, Reilly CA, Jevsevar DS. Cross-specialty PROMIS-global health differential item functioning. Qual Life Res. 2021, 30:2339-48. 10.1007\/s11136-021-02812-6","journal-title":"Qual Life Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer RL","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006, 166:1092-7. 10.1001\/archinte.166.10.1092","journal-title":"Arch Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1476","article-title":"Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis","volume":"365","author":"Levis B","year":"2019","unstructured":"Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019, 365:10.1136\/bmj.l1476","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.10.013","article-title":"COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score","volume":"87","author":"Sletten DM","year":"2012","unstructured":"Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012, 87:1196-201. 10.1016\/j.mayocp.2012.10.013","journal-title":"Mayo Clin Proc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/medsci6040082","article-title":"Low-dose naltrexone (LDN)-review of therapeutic utilization","volume":"6","author":"Toljan K","year":"2018","unstructured":"Toljan K, Vrooman B. Low-dose naltrexone (LDN)-review of therapeutic utilization. Med Sci (Basel). 2018, 6:10.3390\/medsci6040082","journal-title":"Med Sci (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1049909119838974","article-title":"Pharmacology update: low-dose naltrexone as a possible nonopioid modality for some chronic, nonmalignant pain syndromes","volume":"36","author":"Trofimovitch D","year":"2019","unstructured":"Trofimovitch D, Baumrucker SJ. Pharmacology update: low-dose naltrexone as a possible nonopioid modality for some chronic, nonmalignant pain syndromes. Am J Hosp Palliat Care. 2019, 36:907-12. 10.1177\/1049909119838974","journal-title":"Am J Hosp Palliat Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168429","article-title":"Immunometabolic modulatory role of naltrexone in BV-2 microglia cells","volume":"22","author":"Ku\u010di\u0107 N","year":"2021","unstructured":"Ku\u010di\u0107 N, Ra\u010dki V, \u0160verko R, Vidovi\u0107 T, Grahovac I, Mr\u0161i\u0107-Pel\u010di\u0107 J. Immunometabolic modulatory role of naltrexone in BV-2 microglia cells. Int J Mol Sci. 2021, 22:10.3390\/ijms22168429","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00809","article-title":"Naltrexone inhibits IL-6 and TNF\u03b1 production in human immune cell subsets following stimulation with ligands for intracellular toll-like receptors","volume":"8","author":"Cant R","year":"2017","unstructured":"Cant R, Dalgleish AG, Allen RL. Naltrexone inhibits IL-6 and TNF\u03b1 production in human immune cell subsets following stimulation with ligands for intracellular toll-like receptors. Front Immunol. 2017, 8:10.3389\/fimmu.2017.00809","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2008.06321.x","article-title":"Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)","volume":"28","author":"Hutchinson MR","year":"2008","unstructured":"Hutchinson MR, Zhang Y, Brown K, et al.. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008, 28:20-9. 10.1111\/j.1460-9568.2008.06321.x","journal-title":"Eur J Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2018.04.005","article-title":"Autoimmunity in postural orthostatic tachycardia syndrome: current understanding","volume":"215","author":"Vernino S","year":"2018","unstructured":"Vernino S, Stiles LE. Autoimmunity in postural orthostatic tachycardia syndrome: current understanding. Auton Neurosci. 2018, 215:78-82. 10.1016\/j.autneu.2018.04.005","journal-title":"Auton Neurosci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315587566","article-title":"Autoimmune markers and autoimmune disorders in patients with postural tachycardia syndrome (POTS)","volume":"24","author":"Blitshteyn S","year":"2015","unstructured":"Blitshteyn S. Autoimmune markers and autoimmune disorders in patients with postural tachycardia syndrome (POTS). Lupus. 2015, 24:1364-9. 10.1177\/0961203315587566","journal-title":"Lupus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.90a.22093","article-title":"Autoimmunity and postural orthostatic tachycardia syndrome: implications in diagnosis and management","volume":"90","author":"Aboseif A","year":"2023","unstructured":"Aboseif A, Bireley JD, Li Y, Polston D, Abbatemarco JR. Autoimmunity and postural orthostatic tachycardia syndrome: implications in diagnosis and management. Cleve Clin J Med. 2023, 90:439-47. 10.3949\/ccjm.90a.22093","journal-title":"Cleve Clin J Med"},{"key":"ref26","article-title":"Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation","volume":"232","author":"Tempel A","year":"1985","unstructured":"Tempel A, Gardner EL, Zukin RS. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther. 1985, 232:","journal-title":"J Pharmacol Exp Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.08.013","article-title":"Postural tachycardia syndrome: a heterogeneous and multifactorial disorder","volume":"87","author":"Benarroch EE","year":"2012","unstructured":"Benarroch EE. Postural tachycardia syndrome: a heterogeneous and multifactorial disorder. Mayo Clin Proc. 2012, 87:1214-25. 10.1016\/j.mayocp.2012.08.013","journal-title":"Mayo Clin Proc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/176869-low-dose-naltrexone-use-in-postural-orthostatic-tachycardia-syndrome-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:32Z","timestamp":1707509072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/176869-low-dose-naltrexone-use-in-postural-orthostatic-tachycardia-syndrome-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,13]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.43426","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,13]]}}}